Guselkumab - Janssen Biotech

Drug Profile

Guselkumab - Janssen Biotech

Alternative Names: CNTO-1959; TREMFYA; Tremfya

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech; MorphoSys; Taiho Pharmaceutical
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Palmoplantar pustulosis
  • Phase II/III Crohn's disease
  • Phase II Hidradenitis suppurativa; Rheumatoid arthritis

Most Recent Events

  • 22 Oct 2018 Efficacy and adverse events data from the long term VOYAGE-1 phase III trial in Plaque psoriasis released by Janssen Pharmaceutical
  • 20 Sep 2018 Janssen completes enrolment in a phase III trial for Plaque psoriasis in USA, Australia, Canada, Czech Republic, France, Germany, Hungary, Poland and Spain (NCT03090100)
  • 10 Sep 2018 Efficacy and adverse events data from a a phase III trial in Palmoplantar pustulosis released by Janssen Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top